Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN-220 dose comparison in children born small for gestational age with short stature
2017-000914-47Phase 3
- Sponsor
- Novo Nordisk
- Start
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of somatropin in Short stature in children born small for gestational age (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in height standard deviation score for chronological age.
02
Drugs
somatropin
03
Conditions
Short stature in children born small for gestational age
Beyond the preview
Go deeper on 2017-000914-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000914-47.